Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03668847 · ClinicalTrials.gov registry record · Phase 2
DM-CHOC-PEN for Brain Tumors in AYA Subjects
A Phase 2 study of Advanced Cancer and Brain Metastases, sponsored by DEKK-TEC.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT03668847 is a Phase 2 study of Advanced Cancer and Brain Metastases that has completed, run by DEKK-TEC. The registered enrollment target is 20 participants, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03668847, a Phase 2 study of Advanced Cancer and Brain Metastases, has completed, sponsored by DEKK-TEC.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) is a polychlorinated pyridyl cholesterol carbonate that is lipophilic, electrically neural, crosses the blood brain barrier (BBB), ability to localize in intracranial tumor tissue, lacks neurotoxicity and not transported out of the brain via Pgp (p-glycoprotein). DM-CHOC-PEN has completed a Phase I Adolescent and Young Adult (AYA) trial in humans, some of which possessed primary and secondary tumors involving the brain. Complete remissions in both primary (astrocytoma, GBM) and metastatic lung cancers were reported. This Phase II trial is closed for adolescent and young adults (AYA) subjects with advanced cancer - brain involvement is required.
Conditions Studied
Interventions
- DRUG DM-CHOC-PEN
Study Locations (1)
Louisiana
- Tulane University Medical Center - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-01-01 |
| Est. Completion | 2021-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03668847
The ClinicalTrials.gov registry entry for NCT03668847 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (92% lower). The listed sponsor is DEKK-TEC, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Advanced Cancer appearing as the primary indexed condition, and to 1 intervention - of which DM-CHOC-PEN is the first listed.
NCT03668847 reports 1 study location spanning 1 distinct geographic area - top geographies include Louisiana.
Frequently Asked Questions
What is clinical trial NCT03668847 about?
NCT03668847 is a clinical study titled "DM-CHOC-PEN for Brain Tumors in AYA Subjects". 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) is a polychlorinated pyridyl cholesterol carbonate that is lipophilic, electrically neural, crosses the blood brain barrier (BBB), ability to localize in intracranial tumor tissue, lacks neurotoxicity and not transported out of the brain ...
What is the current status of trial NCT03668847?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2019-01-01. Estimated completion is 2021-09-30.
What conditions does trial NCT03668847 study?
This clinical trial studies the following conditions: Advanced Cancer, Brain Metastases.
What interventions are being tested in trial NCT03668847?
The interventions under investigation include: DM-CHOC-PEN (DRUG).
Who is sponsoring clinical trial NCT03668847?
This trial is sponsored by DEKK-TEC, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03668847 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
RECRUITING · Phase 2
-
Psilocybin in Cancer Pain Study
RECRUITING · Phase 2
-
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
RECRUITING · Phase 2
-
Psilocybin Therapy in Advanced Cancer
RECRUITING · Phase 2
-
Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.